Fragile X syndrome, the most common inherited cause of intellectual disability, has long challenged scientists searching for treatments that improve learning and memory without producing unacceptable side effects. A new study published in Translational Psychiatry adds an important piece to that puzzle, reporting that the pro-cognitive effects of AM6545 in a mouse model of fragile X syndrome involve the brain’s serotonergic system. The finding shifts attention toward a signaling network better known for regulating mood, sleep, appetite and sensory processing, suggesting that serotonin may help translate the actions of AM6545 into measurable improvements in cognition.
Fragile X syndrome is caused by the loss or severe reduction of fragile X messenger ribonucleoprotein, commonly known as FMRP. This protein normally helps control the production of many other proteins at synapses, the microscopic junctions through which neurons communicate. When FMRP is absent, synaptic signaling becomes unusually responsive and poorly regulated. The resulting changes can affect learning, memory, attention, sensory processing and social behavior. In humans, fragile X syndrome is also frequently associated with anxiety, hyperactivity, autistic features and seizures, making the disorder biologically complex rather than a condition defined by a single cognitive impairment.
AM6545 belongs to a class of compounds that interact with the endocannabinoid system, a neuromodulatory network that helps regulate communication between neurons. The compound is designed to act on cannabinoid CB1 receptors, which are widely distributed throughout the brain and are involved in controlling the release of several neurotransmitters. Unlike cannabis-derived compounds that can directly activate CB1 receptors and produce psychoactive effects, AM6545 has been investigated as a negative allosteric modulator. In technical terms, it binds to a regulatory site on the receptor and changes how the receptor responds, potentially reducing excessive signaling while avoiding the full pharmacological profile of a conventional CB1 antagonist.
That distinction matters because the endocannabinoid system is deeply involved in synaptic plasticity, the capacity of neural connections to strengthen or weaken in response to experience. Synaptic plasticity is considered a cellular foundation for learning and memory. In fragile X syndrome, however, the balance between excitation and inhibition in neural circuits can be disrupted, and several studies have implicated abnormal endocannabinoid signaling in that imbalance. By modifying CB1 receptor activity, AM6545 may influence the release of neurotransmitters and help restore more stable communication within circuits involved in cognition. The new research indicates that this process is not limited to cannabinoid signaling itself.
The study by de los Reyes-Ramírez, Bergadà-Martínez, Martínez-Torres and colleagues identifies serotonergic signaling as a mechanism involved in AM6545’s pro-cognitive action in a mouse model of fragile X syndrome. Serotonin, or 5-hydroxytryptamine, is produced by a relatively small group of neurons concentrated mainly in the raphe nuclei of the brainstem. From there, serotonergic projections extend across broad regions, including the hippocampus and prefrontal cortex—areas essential for memory formation, attention and flexible decision-making. Serotonin acts through multiple receptor families, each capable of triggering distinct intracellular responses, so describing a “serotonergic mechanism” does not imply a single universal serotonin pathway.
Instead, the finding suggests that AM6545’s cognitive effects may depend partly on how the compound changes serotonin release, receptor activity or the responsiveness of neural circuits to serotonergic input. This is scientifically significant because serotonin and the endocannabinoid system are not isolated networks. They communicate at several levels: cannabinoid receptors can influence neurotransmitter release from serotonergic terminals, while serotonin receptors can alter the activity of circuits that also receive endocannabinoid regulation. Such cross-talk provides a plausible biological route by which a compound acting at CB1 receptors could produce effects that ultimately require serotonin signaling.
In animal research, evidence for this type of mechanism generally comes from combining behavioral tests with pharmacological or neurobiological interventions that selectively interfere with serotonergic transmission. When a compound improves performance in tasks measuring learning or memory, and that improvement is reduced or eliminated when serotonin receptors or related pathways are blocked, researchers can infer that serotonergic signaling contributes to the observed effect. The study’s central conclusion is therefore not simply that AM6545 changes behavior in a fragile X model, but that its cognitive benefit is linked to a specific neurotransmitter system. That distinction helps move the field from descriptive findings toward a more mechanistic understanding of drug action.
The implications extend beyond one experimental compound. Current clinical management of fragile X syndrome focuses largely on symptoms, using behavioral interventions and medications aimed at problems such as anxiety, attention difficulties, irritability, sleep disruption or seizures. No broadly approved treatment directly corrects the molecular cause of the syndrome or reliably restores cognitive function. A treatment strategy that engages both endocannabinoid and serotonergic biology could eventually offer new options, but the path from a mouse model to human therapy is long. Doses, metabolism, receptor distribution and safety margins can differ substantially between species, and improvements in laboratory tasks do not automatically predict meaningful gains in human learning or daily functioning.
The findings also raise questions that future studies will need to answer. Researchers will need to determine which serotonin receptor subtypes are essential, which brain regions are most important, and whether the response depends on the developmental stage or the severity of fragile X-related abnormalities. It will also be important to establish whether AM6545 improves multiple cognitive domains or primarily affects particular forms of memory, attention or behavioral flexibility. Long-term studies must examine tolerance, emotional effects, motor consequences and possible interactions with medications that already influence serotonin or cannabinoid signaling. These details will determine whether the mechanism is a promising therapeutic avenue or mainly a guide to understanding circuit dysfunction.
For now, the study offers a sharper view of how cognition may be altered in fragile X syndrome and how it might be pharmacologically improved. Its message is not that serotonin alone explains the disorder, nor that AM6545 is ready for clinical use. Rather, it reveals that the cognitive effects of manipulating cannabinoid receptor signaling can depend on communication with the serotonergic system. In a field where complex neurological symptoms arise from the interaction of many molecular pathways, that kind of mechanistic link is valuable. It gives researchers a new target for experiments—and a possible blueprint for designing treatments that aim not merely to suppress symptoms, but to stabilize the neural networks underlying learning and memory.
Subject of Research: Serotonergic mechanisms underlying the pro-cognitive effects of AM6545 in a mouse model of fragile X syndrome.
Article Title: A serotonergic mechanism is involved in the pro-cognitive effect of AM6545 treatment in a mouse model of fragile X syndrome.
Article References: de los Reyes-Ramírez, L., Bergadà-Martínez, A., Martínez-Torres, S. et al. “A serotonergic mechanism is involved in the pro-cognitive effect of AM6545 treatment in a mouse model of fragile X syndrome.” Translational Psychiatry (2026). https://doi.org/10.1038/s41398-026-04360-4
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41398-026-04360-4
Keywords: fragile X syndrome, AM6545, serotonin, serotonergic signaling, endocannabinoid system, CB1 receptor, cognition, synaptic plasticity, mouse model, neurobiology
